Orphan Drug Status Granted for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196) NEW CANAAN, CT--(Marketwire - January 22, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced today that its triphendiol (previously known as NV-196) has been granted orphan drug status by the...